MGNX: Major cash infusions and pipeline progress set stage for innovation and clinical milestones – TradingView
Significant non-dilutive capital from royalty and manufacturing deals extends runway through 2028, enabling robust investment in a diversified pipeline. Key clinical updates are expected for lorigerlimab and next-gen ADCs, with a focus on innovation and strategic collaborations.
Based on MacroGenics, Inc. [MGNX] Stifel 2026 Targeted Oncology Virtual Forum Audio Transcript — May. 20 2026
Select market data provided by ICE Data Services. Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.Copyright © 2026, American Bankers Association. CUSIP Database provided by FactSet Research Systems Inc. All rights reserved. SEC fillings and other documents provided by Quartr.© 2026 TradingView, Inc.
source
This article was autogenerated from a news feed from CDO TIMES selected high quality news and research sources. There was no editorial review conducted beyond that by CDO TIMES staff. Need help with any of the topics in our articles? Schedule your free CDO TIMES Tech Navigator call today to stay ahead of the curve and gain insider advantages to propel your business!
Based on MacroGenics, Inc. [MGNX] Stifel 2026 Targeted Oncology Virtual Forum Audio Transcript — May. 20 2026
Select market data provided by ICE Data Services. Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.Copyright © 2026, American Bankers Association. CUSIP Database provided by FactSet Research Systems Inc. All rights reserved. SEC fillings and other documents provided by Quartr.© 2026 TradingView, Inc.
source
This article was autogenerated from a news feed from CDO TIMES selected high quality news and research sources. There was no editorial review conducted beyond that by CDO TIMES staff. Need help with any of the topics in our articles? Schedule your free CDO TIMES Tech Navigator call today to stay ahead of the curve and gain insider advantages to propel your business!
